Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
BPMC Analyst Ratings
Moderate Buy
11 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BPMC Stock 12 Month Forecast
Average Price Target
$126.93
▲(34.53% Upside)
| Highest Price Target$155.00 | Average Price Target$126.93 | Lowest Price Target$93.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Stifel Nicolaus
Reiterated
02/20/25
Barclays
Reiterated
02/18/25
JMP Securities
Reiterated
02/18/25
Robert W. Baird
Reiterated
02/14/25
Needham
Reiterated
02/14/25
Morgan Stanley
Reiterated
02/14/25
Leerink Partners
Reiterated
02/14/25
TD Cowen
Reiterated
02/13/25
Wells Fargo
Reiterated
02/13/25
H.C. Wainwright
Reiterated
02/13/25
Oppenheimer
$130
Buy
37.78%
Upside
Reiterated
02/13/25
Oppenheimer Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)
Raymond James
$130
Buy
37.78%
Upside
Reiterated
02/03/25
Raymond James reiterates Strong Buy Rating on Blueprint Medicines (BPMC)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $130.00 price target on Blueprint Medicines (NASDAQ: BPMC)
J.P. Morgan
$126→$129
Buy
36.72%
Upside
Reiterated
02/03/25
Analysts Offer Insights on Healthcare Companies: Twist Bioscience (NASDAQ: TWST), Cardinal Health (NYSE: CAH) and Blueprint Medicines (NASDAQ: BPMC)
Piper Sandler
$119
Hold
26.13%
Upside
Assigned
01/27/25
Analysts Offer Insights on Healthcare Companies: Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Blueprint Medicines (NASDAQ: BPMC)
Wedbush
$124
Buy
31.43%
Upside
Reiterated
01/13/25
Blueprint Medicines (BPMC) PT Lowered to $124 at WedbushWedbush analyst David Nierengarten lowered the price target on Blueprint Medicines (NASDAQ: BPMC) to $124.00 (from $135.00) while maintaining a Outperform rating.
Best Analysts Covering Blueprint Medicines
Which Analyst Should I Follow If I Want to Buy BPMC and Sell After:
1 Month
xxx
Success Rate
15/23 ratings generated profit
Average Return
+3.23%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.22% of your transactions generating a profit, with an average return of +3.23% per trade.
3 Months
xxx
Success Rate
13/22 ratings generated profit
Average Return
+6.62%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +6.62% per trade.
1 Year
Success Rate
16/23 ratings generated profit
Average Return
+17.73%
reiterated a buy rating 9 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +17.73% per trade.
2 Years
xxx
Success Rate
21/23 ratings generated profit
Average Return
+26.93%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 91.30% of your transactions generating a profit, with an average return of +26.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BPMC Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
9
8
6
3
4
Buy
12
7
8
10
17
Hold
10
9
10
9
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
24
24
22
32
Each month's total comprises the sum of three months' worth of ratings.
BPMC Financial Forecast
BPMC Stock Forecast FAQ
What is BPMC’s average 12-month price target, according to analysts?
Based on analyst ratings, Blueprint Medicines’s 12-month average price target is $126.93.
What is BPMC’s upside potential, based on the analysts’ average price target?
Blueprint Medicines has 34.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BPMC a Buy, Sell or Hold?
Blueprint Medicines has a consensus rating of Moderate Buy which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.
What is Blueprint Medicines’s price target?
The average price target for Blueprint Medicines is $126.93. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $155.00 ,the lowest forecast is $93.00. The average price target represents 34.53% Increase from the current price of $94.35.
The highest analyst price target is $155.00 ,the lowest forecast is $93.00. The average price target represents 34.53% Increase from the current price of $94.35.
What do analysts say about Blueprint Medicines?
Blueprint Medicines’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of BPMC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.